4M 4D Molecular Therapeutics, Inc. Stock: price and insider trades · United States · SEC (Form 4)Source id SEC:4d-molecular-therapeutics-inc-b82dc6 US · SEC (Form 4) Mcap US$810.4M Track the 4D Molecular Therapeutics, Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €810.4m. The latest transaction was reported on 3 September 2026 (Levée d'options). Among the most active insiders: Bizily Scott. All data is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
All Executives85 Thresholds0 Prospectus0 Other0
Declarations 85 total
◇ Chief Legal Officer · Executives · 1 Sept 2026
584 shares @ US$6.49 Common Stock SEC:0001193125-26-382245:0
▼ Chief Legal Officer · Executives · 1 Sept 2026
584 shares @ US$14.00 Common Stock SEC:0001193125-26-382245:1
◇ See Remarks · Executives · 19 Aug 2026
50,000 shares @ US$4.14 0.023% mcap 2.7% of flow Common Stock SEC:0001193125-26-361096:0
▼ See Remarks · Executives · 19 Aug 2026
43,149 shares @ US$15.3566 0.072% mcap 8.7% of flow Common Stock SEC:0001193125-26-361096:1
▼ See Remarks · Executives · 19 Aug 2026
25,927 shares @ US$16.4173 0.046% mcap 5.6% of flow Common Stock SEC:0001193125-26-361096:2
● Officer · Executives · 19 Aug 2026
69,076 shares @ US$16.76 0.13% mcap 32.8% of flow Class A Common SEC144:0001958244-26-000539
● Officer · Executives · 17 Aug 2026
6,540 shares @ US$12.19 0.0087% mcap 27.6% of flow COMMON SEC144:0001950047-26-008269
◇ Chief Legal Officer · Executives · 13 Aug 2026
1,635 shares @ US$4.14 0.0007% mcap 1.1% of flow Common Stock SEC:0001193125-26-354313:0
▼ Chief Legal Officer · Executives · 13 Aug 2026
1,635 shares @ US$12.00 0.0021% mcap 3.3% of flow Common Stock SEC:0001193125-26-354313:1
▼ Chief Legal Officer · Executives · 17 Aug 2026
1,635 shares @ US$12.20 0.0022% mcap 3.3% of flow Common Stock SEC:0001193125-26-354313:3
◇ Chief Legal Officer · Executives · 17 Aug 2026
1,635 shares @ US$4.14 0.0007% mcap 1.1% of flow Common Stock SEC:0001193125-26-354313:2
● Officer · Executives · 13 Aug 2026
1,635 shares @ US$11.87 0.0021% mcap 9.3% of flow COMMON SEC144:0001950047-26-008088
▼ See Remarks · Executives · 4 Aug 2026
26,842 shares @ US$10.2301 0.030% mcap 4.4% of flow Common Stock SEC:0001193125-26-335115:0
● Officer · Executives · 4 Aug 2026
26,842 shares @ US$10.26 0.030% mcap 11.7% of flow Class A Common SEC144:0001958244-26-000477
▼ See Remarks · Executives · 3 Aug 2026
12,415 shares @ US$10.0461 0.014% mcap 2.1% of flow Common Stock SEC:0001193125-26-333014:0
● Officer · Executives · 3 Aug 2026
12,415 shares @ US$10.09 0.014% mcap 6.0% of flow Class A Common SEC144:0001958244-26-000473
▼ See Remarks · Executives · 9 Jul 2026
42,608 shares @ US$12.8656 0.061% mcap 9.4% of flow Common Stock SEC:0001834021-26-000004:0
▼ See Remarks · Executives · 10 Jul 2026
442 shares @ US$12.8355 0.0006% mcap 0.1% of flow Common Stock SEC:0001834021-26-000004:2
▼ See Remarks · Executives · 10 Jul 2026
15,283 shares @ US$12.0107 0.020% mcap 3.2% of flow Common Stock SEC:0001834021-26-000004:1
● Officer · Executives · 10 Jul 2026
15,725 shares @ US$12.31 0.021% mcap 26.0% of flow Class A Common SEC144:0001958244-26-000446
● Officer · Executives · 9 Jul 2026
42,608 shares @ US$12.89 0.061% mcap 100.0% of flow Class A Common SEC144:0001958244-26-000444
◇ Chief Legal Officer · Executives · 30 Jun 2026
814 shares Common Stock SEC:0001920738-26-000004:0
◇ Chief Legal Officer · Executives · 30 Jun 2026
5,752 shares Common Stock SEC:0001920738-26-000004:1
▼ Chief Legal Officer · Executives · 30 Jun 2026
6,566 shares Common Stock SEC:0001920738-26-000004:2
● Officer · Executives · 30 Jun 2026
6,566 shares @ US$12.88 0.0094% mcap 100.0% of flow COMMON SEC144:0001950047-26-006669
25 of 85 declarations
Load more (60 remaining) 关于 4D Molecular Therapeutics, Inc. 4D Molecular Therapeutics, Inc. 是一家生物制药公司，专注于开发用于治疗遗传性疾病的基因疗法。它利用病毒载体技术平台设计靶向治疗方案。